CURE’s gastric cancer page is a go-to resource for oncology news and updates in the world of gastric cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in gastric cancer.
May 3rd 2024
For certain patients with HER2-positive gastric cancers, a Keytruda treatment combination has shown promising survival outcomes.
As We Enter a New Era of Cancer Treatment, I’m Taking Caution in Headlines Highlighting a Cure
June 14th 2022Recent headlines have been highlighting a monoclonal antibody that eliminated evidence of disease in patients with rectal cancer, but I believe that findings from the research need to be taken with a few grains of caution.
Skin-Related Side Effects From a Certain Cancer Treatment May Indicate Stronger Responses, Survival
January 28th 2022Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.
FDA Approves Opdivo for Adjuvant Treatment of Esophageal and Gastroesophageal Junction Cancer
May 20th 2021Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this occurred.
FDA Approves Keytruda for Use With Trastuzumab and Chemotherapy for Subtypes of Stomach Cancer
May 5th 2021Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
April 16th 2021The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.